Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2019

01-02-2019 | Correspondence

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol

Authors: Vicenç Torrente-Segarra, Manuel Fernandez Prada, Rosa Expósito Moliner, Noemí Patricia Garrido Puñal, Amalia Sánchez-Andrade Fernández, José Ramón Lamua Riazuelo, Alejandro Olivé, Juan Víctor Tovar Beltrán, RENACER Study Group (REgistro NAcional CERtolizumab)

Published in: Rheumatology International | Issue 2/2019

Login to get access

Excerpt

Dear Editor, …
Appendix
Available only for authorised users
Literature
1.
Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P et al (2014) Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 73:2094–2100CrossRefPubMed
2.
Keystone E, Heijde D, Mason D Jr, Landewe´ R, Vollenhoven RV, Combe B et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58:3319–3329CrossRefPubMed
3.
Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C (2007) Physicians of the Swiss clinical quality management program for rheumatoid arthritis. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 57:679–685CrossRefPubMed
4.
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322CrossRef
5.
Murota A, Kaneko Y, Yamaoka K, Takeuchi T (2016) Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol 43:1984–1988CrossRef
6.
Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L (2018) Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 36:29–35
7.
Tornero Molina J, Sanmartí Sala R, Rodríguez Valverde V, Martín Mola E, Marenco de la Fuente JL, González Álvaro I, Muñoz Fernández S, Gómez-Reino Carnota J, Carreño Pérez L, Batlle Gualda E, Balsa Criado A, Andreu JL, Alvaro-Gracia JM, Martínez López JA, Loza Santamaría E (2010) Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin 6:23–36CrossRefPubMed
8.
Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF (2005) Survival and safety of treatment with infliximab in the elderly population. Rheumatology 44:695–696CrossRefPubMed
Metadata
Title
How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol
Authors
Vicenç Torrente-Segarra
Manuel Fernandez Prada
Rosa Expósito Moliner
Noemí Patricia Garrido Puñal
Amalia Sánchez-Andrade Fernández
José Ramón Lamua Riazuelo
Alejandro Olivé
Juan Víctor Tovar Beltrán
RENACER Study Group (REgistro NAcional CERtolizumab)
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4205-z

Other articles of this Issue 2/2019

Rheumatology International 2/2019 Go to the issue

Systematic Review

Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review

Comorbidities

Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies

Case Based Review

Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature

Observational Research

Raynaud’s phenomenon in Northern Sweden: a population-based nested case–control study

Observational Research

Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Cases with a Message

Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits